Straits Times Index
3,428.34 -11.54 (-0.34%) Nikkei
41,044.42 +130.77 (+0.32%) Hang Seng
17,930.16 -98.12 (-0.54%) FTSE 100
8,241.26 +70.14 (+0.86%) Bitcoin USD
57,084.09 -1,800.18 (-3.06%) CMC Crypto 200
1,185.41 -75.78 (-6.00%)
Quest Diagnostics Inc (QDI.DU)
| Previous close | 126.35 |
| Open | 129.60 |
| Bid | 129.90 x 0 |
| Ask | 130.55 x 0 |
| Day's range | 129.60 - 129.60 |
| 52-week range | 113.25 - 133.60 |
| Volume | |
| Avg. volume | 0 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 23 Jul 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
ZacksQuest Diagnostics (DGX) to Expand in Canada With LifeLabs Buyout
By integrating LifeLabs into its operations, Quest Diagnostics (DGX) aims to enhance the accessibility and quality of diagnostic services for Canadians.
- Reuters
Quest Diagnostics expands into Canada with nearly $1 billion LifeLabs deal
LifeLabs, which provides community laboratory tests, would retain its brand, Canadian headquarters and management after the acquisition is closed. The U.S. laboratory operator will acquire 100% of the equity of LifeLabs and expects to fund the acquisition through cash on hand and debt.
PR NewswireQuest Diagnostics to Acquire LifeLabs from OMERS, Enhancing Diagnostic Services for Canadians
Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced a definitive agreement with OMERS to acquire LifeLabs, a trusted provider of community laboratory tests for millions of Canadians, for a value of approximately CAN $1.35 billion (approximately USD $985 million), including net debt.
